Metformin burns glucose in gut, study

Metformin is the default diabetes pill partly because it works, partly because it is cheap, and partly because doctors know it so well. But one basic question has stayed weirdly unsettled for years — where does the drug actually do its most important work? A new Northwestern study in mice argues that the answer is the gut. More specifically, cells lining the intestine seem to pull extra glucose out of circulation and burn it locally after metformin slows their mitochondria. ### Wait — wasn’t metformin a liver drug? That has been the standard story for a long time. Metformin was widely taught as a drug that mainly lowers glucose by suppressing glucose production in the liver. But the picture never fully fit. Standard doses create especially high metformin concentrations in the intestine, and earlier work had already hinted that the gut was doing more than just absorbing the pill. (nature.com) ### What changed in this study? The new paper tied metformin’s glucose-lowering effect to mitochondrial complex I inhibition in the intestinal epithelium — the layer of cells that lines the gut. The researchers used mouse genetics and human metabolomic clues to show that when this gut-specific pathway was blocked, several hallmark effects of metformin weakened or disappeared. That let them move from “the gut seems involved” to “this tissue and this mechanism are load-bearing.” (cell.com) ### What does the gut actually do here? Basically, metformin makes the intestine act like a glucose sink. When complex I is inhibited, gut cells shift how they make energy. They pull in more glucose and run more of it through glycolysis, converting some of that carbon into lactate and lactoyl-phenylalanine. In plain English, the gut starts chewing through more sugar itself instead of leaving as much in the bloodstream. (nature.com) ### Why does mitochondrial complex I matter? Complex I is part of the cell’s energy machinery. If you slow it, the cell has to rebalance how it gets fuel. In intestinal cells, that seems to push metabolism toward heavier glucose use. One useful way to picture it is a hybrid car whose main engine suddenly gets throttled back — the system leans harder on the backup route. Here, the backup route is glucose processing in the gut lining. (pubmed.ncbi.nlm.nih.gov) ### Did the study say anything beyond blood sugar? Yes — and this is part of why the result is interesting. The same gut mechanism also helped explain other metformin-linked signals, including lower citrulline and higher GDF15 and N-lactoyl-phenylalanine. Those are not random side notes. They connect this one mechanism to several clinical fingerprints people have been seeing around metformin for years. (nature.com) ### What about berberine? The paper also pointed to berberine — the supplement often hyped online as “nature’s Ozempic” — hitting a similar intestinal pathway. That does not make berberine equivalent to metformin, and it definitely does not make it an Ozempic substitute. But it does suggest some glucose-lowering compounds may converge on the same gut energy circuit. ### So does this overturn the old model? (pubmed.ncbi.nlm.nih.gov) Not completely. It is better to think of this as a rebalance than a total reversal. The liver still matters in glucose control. But this work argues that the intestine may be the primary site that kicks off several of metformin’s best-known effects, at least in these models. The catch is that this was preclinical work in mice, even though the researchers also used human metabolomic data to support the mechanism. (news.northwestern.edu) ### Bottom line? The big idea is simple — metformin may lower blood sugar not just by telling the liver to make less glucose, but by making the gut burn more of it. If that holds up in humans, drug developers may start treating the intestine less like plumbing and more like a frontline metabolic organ. (nature.com) (pubmed.ncbi.nlm.nih.gov)